Table 1.
Demographics and clinicopathologic features of 174 patients with NSCLC.
Figure 1.
Pie chart of EGFR, KRAS, HER2 and BRAF mutation spectrum from 107 lung adenocarcinomas.
The mutation rates of EGFR, KRAS, HER2 and BRAF were 25.2, 5.6, 1.8 and 0.9%, respectively.
Figure 2.
Relapse-free survival and overall survival in patients with NSCLC.
EGFR and KRAS mutation status were not associated with relapse-free survival (P = 0.600) or overall survival (P = 0.873) in lung adenocarcinoma; c–d. Lymphnode stage (N stage) was significantly associated with relapse-free survival (P = 0.001) or overall survival (P = 0.001) in NSCLC.
Table 2.
Association between clinical and molecular factors and disease relapse.